These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 1977597)

  • 1. Benextramine: a long-lasting neuropeptide Y receptor antagonist.
    Doughty MB; Chu SS; Miller DW; Li K; Tessel RE
    Eur J Pharmacol; 1990 Aug; 185(1):113-4. PubMed ID: 1977597
    [No Abstract]   [Full Text] [Related]  

  • 2. Role of sulfhydryl groups in Y2 neuropeptide Y receptor binding activity.
    Li W; MacDonald RG; Hexum TD
    J Biol Chem; 1992 Apr; 267(11):7570-5. PubMed ID: 1348506
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benextramine-neuropeptide Y receptor interactions: contribution of the benzylic moieties to [3H]neuropeptide Y displacement activity.
    Doughty MB; Chaurasia CS; Li K
    J Med Chem; 1993 Jan; 36(2):272-9. PubMed ID: 8093737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding profile of benextramine at neuropeptide Y receptor subtypes in rat brain areas.
    Melchiorre C; Romualdi P; Bolognesi ML; Donatini A; Ferri S
    Eur J Pharmacol; 1994 Nov; 265(1-2):93-8. PubMed ID: 7883034
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Possible location and function of neuropeptide Y receptor subtypes in the rat mesenteric arterial bed.
    McAuley MA; Westfall TC
    J Pharmacol Exp Ther; 1992 Jun; 261(3):863-8. PubMed ID: 1351098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benextramine, a putative neuropeptide Y receptor antagonist, attenuates the termination of receptivity.
    Clark JT
    Physiol Behav; 1992 Nov; 52(5):965-9. PubMed ID: 1362460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Failure of the putative neuropeptide Y antagonists, benextramine and PYX-2, to inhibit Y2 receptors in rat isolated prostatic vas deferens.
    Palea S; Corsi M; Rimland JM; Trist DG; Ratti E
    Br J Pharmacol; 1995 Nov; 116(5):2401-6. PubMed ID: 8581275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between alterations in alpha 1-adrenoceptor reserve by phenoxybenzamine and benextramine and the sensitivity of cirazoline-induced pressor responses to inhibition by nifedipine.
    Nichols AJ; Ruffolo RR
    Eur J Pharmacol; 1986 Jul; 126(3):297-301. PubMed ID: 2875887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of neuropeptide Y and [Leu31,Pro34] neuropeptide Y on experimental gastric lesion formation and gastric secretion in the rat.
    Penner SB; Smyth DD; Glavin GB
    J Pharmacol Exp Ther; 1993 Jul; 266(1):339-43. PubMed ID: 8101219
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Demonstration of alpha 1s-adrenoceptors after exposure of the rat anococcygeus to benextramine.
    Coates J; Weetman DF
    Br J Pharmacol; 1983 Oct; 80(2):343-6. PubMed ID: 6140059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pertussis toxin treatment counteracts intramembrane interactions between neuropeptide Y receptors and alpha 2-adrenoceptors.
    Von Euler G; Fuxe K; Van der Ploeg I; Fredholm BB; Agnati LF
    Eur J Pharmacol; 1989 Dec; 172(6):435-41. PubMed ID: 2558898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The irreversible alpha-blocker benextramine interacts with two different thiol groups.
    Melchiorre C; Gallucci P
    Farmaco Sci; 1983 Dec; 38(12):950-6. PubMed ID: 6141952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alpha 2-adrenergic receptor turnover in adipose tissue and kidney: irreversible blockade of alpha 2-adrenergic receptors by benextramine.
    Taouis M; Berlan M; Lafontan M
    Mol Pharmacol; 1987 Jan; 31(1):89-96. PubMed ID: 2880286
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuronal mechanism of the inhibitory effect of calcitonin on N-methyl-D-aspartate-induced aversive behavior.
    Maeda Y; Yamada K; Hasegawa T; Nabeshima T
    Eur J Pharmacol; 1995 Mar; 275(2):163-70. PubMed ID: 7796851
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benextramine and nifedipine distinguish between sub-classes of alpha 1-adrenoceptors.
    Tabrizchi R; Triggle CR
    Life Sci; 1989; 45(26):2577-85. PubMed ID: 2559276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of benextramine as an irreversible alpha-adrenergic blocker and as a blocker of potassium-activated calcium channels.
    Plotek Y; Atlas D
    Eur J Biochem; 1983 Jul; 133(3):539-44. PubMed ID: 6134617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N,N''-(dithio-2,1-ethanediyl)bis[N'-(pyrrol-2-ylmethyl)-1, 6,- hexanediamine] (pyrextramine), a new irreversible alpha 1-adrenoreceptor blocking agent of the tetramine disulfide class.
    Brasili L; Angeli P; Brancia E; Melchiorre C
    Eur J Pharmacol; 1984 Aug; 103(1-2):181-4. PubMed ID: 6148255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identical antagonist selectivity of central and peripheral alpha 1-adrenoceptors.
    Timmermans PB; Ali FK; Kwa HY; Schoop AM; Slothorst-Grisdijk FP; van Zwieten PA
    Mol Pharmacol; 1981 Sep; 20(2):295-301. PubMed ID: 6117785
    [No Abstract]   [Full Text] [Related]  

  • 19. Phenoxybenzamine and benextramine, but not 4-diphenylacetoxy-N-[2-chloroethyl]piperidine hydrochloride, display irreversible noncompetitive antagonism at G protein-coupled receptors.
    Bodenstein J; Venter DP; Brink CB
    J Pharmacol Exp Ther; 2005 Aug; 314(2):891-905. PubMed ID: 15857948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of adrenaline-induced platelet aggregation by the alpha-adrenoceptor blocking drug benextramine.
    Belleau B; Benfey BG; Melchiorre C; Montambault M
    Br J Pharmacol; 1982 Jun; 76(2):253-7. PubMed ID: 6124293
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.